You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The 45-minute test was developed by BioMérieux subsidiary BioFire Defense and can be used on the company's FilmArray and FilmArray Torch systems.
Labrador Diagnostics, a firm controlled by an investment group that acquired Theranos' IP, alleged BioFire's FilmArray products infringe two patents.
Technology partners on the study include BioMérieux and SkylineDx, as well as Imperial College London's biomedical electronics unit.
The company announced the launch of the new products in the US and Europe as part of a product portfolio it has named Panther Scalable Solutions.
Perceptive Advisors led the round, joined by new and existing investors. ArcherDx will use the proceeds to launch a companion diagnostic and expand globally.
The firm will use the new funds to accelerate development of products, expand partnerships, and support commercialization of its two multiplex panels.
The firm has entered the market in Africa with a new collaboration in Ghana. It is also developing instrument-agnostic STI and liquid biopsy tests.
ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.
CareDx claims that Natera is infringing on two of its patents related to non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.
ArcherDX plans to keep its research and development efforts in its current facility and move its clinical and commercial testing operations to Baby Gene's CLIA lab.